Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea
- 4 June 2026
- journal article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (4)
Abstract
Sialorrhea significantly impairs quality of life in children with neurodisabilities, including cerebral palsy, yet safe and effective pharmacologic treatment options remain limited. Although atropine is widely used for sialorrhea, it is most commonly used off-label as ophthalmic drops administered intraorally, an approach constrained by poor mucosal retention, frequent dosing, medication-error risk, and systemic anticholinergic adverse effects. To address these limitations, we developed a novel mucoadhesive atropine oral gel (0.01% weight/weight (w/w)) to enhance intraoral residence time and support controlled local and systemic exposure. The pharmacokinetics and safety of the atropine gel were evaluated in a Phase I clinical trial in healthy adults, which informed the development and validation of a physiologically based pharmacokinetic (PBPK) model incorporating a mechanistic oral cavity framework. The oral cavity PBPK model accounts for salivary flow, mucosal absorption, swallowing, and saliva-tissue exchange across six compartments, enabling predictions of local and systemic exposure and evaluation of formulation-relevant determinants of intraoral absorption. Pediatric PBPK simulations were scaled from the adult model using Population Estimates for Age-Related Physiology™ (PEAR Physiology™) to support model-informed dose selection. Simulations identified a minimum pediatric dose range of 0.25 mg/kg once or twice daily, with twice-daily dosing to maintain plasma concentrations within the established minimum effective and maximum tolerated concentration range. Collectively, this work demonstrates the utility of PBPK modeling as a translational tool to integrate formulation attributes, oral cavity physiology, and pediatric dose selection, and supports the clinical advancement of mucoadhesive atropine gel as a safer alternative to off-label intraoral atropine eye drops.Keywords
All Related Versions
Funding Information
- Primary Children's Hospital Foundation
- National Institutes of Health (R03EB033576)
- National Center for Advancing Translational Sciences (UL1TR002538 and UM1TR004409)
This publication has 83 references indexed in Scilit:
- Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug DevelopmentClinical Pharmacology & Therapeutics, 2025
- Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model‐Informed Drug Development PerspectiveClinical Pharmacology & Therapeutics, 2025
- The role of radiation therapy in the management of sialorrhea: A systematic reviewThe Laryngoscope, 2015
- Interventions for drooling in children with cerebral palsy2012
- Measurement of epithelial thickness within the oral cavity using optical coherence tomographyHead & Neck, 2012
- Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonismMovement Disorders, 2007
- Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot studyMovement Disorders, 2002
- NHANES III Health Data Relevant for Aging NationJAMA, 1997
- Atropine Poisoning in Children During the Persian Gulf CrisisJAMA, 1992
- Cross‐over trials, carry‐over effects and the art of self‐delusionStatistics in Medicine, 1988